ANTIKÖRPER GEGEN IL-1 BETA

European patent · EP1313769 · Deleted

Register entry

Publication number
EP1313769
Application number
EP01976118
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Maintained in amended form
Filed
Aug 20, 2001
Published
May 28, 2003
Granted
May 21, 2008
Deleted
Aug 19, 2021
Reason
Maximum term reached
IPC classes
C07K 16/24 (2006.01)
A61K 39/395 (2006.01)
Priority
GB 0020685 22.08.2000
PCT application
PCT/EP2001/009588 20.08.2001
PCT publication
WO2002/016436 28.02.2002
Filing language
English
Source
Swissreg

Supplementary protection certificates

A certificate extends the patent’s protection for a medicine or a plant protection product authorised in Switzerland.

Canakinumab

C01313769/01 · Medicine · Granted · Protection from Aug 20, 2021 to Jul 5, 2024

Authorisation 59226 (Swissmedic, Jul 6, 2009)

Deleted, Maximum term reached

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 23, 2021

    Maximum term reached

    Published in Swissreg on 23.08.2021

  2. Nov 10, 2011

    Change

    Published in Swissreg on 10.11.2011

  3. Jun 30, 2008

    Granted

    Published in +pat+ No 12 in 2008

Parties

Holder

Novartis AG

Lichtstrasse 35, 4056 Basel

Inventor

GRAM, Hermann

79576 Weil, DE

DI PADOVA, Franco, E.

CH-4127 Birsfelden

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.